Inhibrx Submits BLA for Chondrosarcoma and Reports Strong Colorectal Cancer Trial Data for Ozekibart

summarizeSummary

Inhibrx Biosciences submitted a BLA for ozekibart in chondrosarcoma and reported positive interim Phase 1/2 data for ozekibart in colorectal cancer, showing superior efficacy compared to historical benchmarks.

check_boxKey Events

• BLA Submitted for Chondrosarcoma

  Inhibrx submitted a Biologics License Application (BLA) to the FDA for ozekibart (INBRX-109) in conventional chondrosarcoma in April 2026, fulfilling a plan outlined in the recent 10-K filing.

• Positive Interim Phase 1/2 Data in Colorectal Cancer

  Updated interim data from the Phase 1/2 study of ozekibart in combination with FOLFIRI for late-line colorectal cancer showed an Objective Response Rate (ORR) of 20% (vs. historical 1-6%) and a Disease Control Rate (DCR) of 87% in heavily pretreated patients.

• Strong Efficacy and Manageable Safety Profile

  The study reported a median Progression-Free Survival (PFS) of 5.5 months, with 42% of patients remaining progression-free at 6 months. The safety profile was manageable, with most adverse events being Grade 1 or 2 and consistent with FOLFIRI.

• Plans for Accelerated Pathways and First-Line CRC Trial

  The company plans to meet with the FDA in the second half of 2026 to discuss initiating a first-line registrational trial in colorectal cancer and exploring accelerated regulatory pathways for ozekibart in fourth-line CRC and refractory Ewing sarcoma.

auto_awesomeAnalysis

Inhibrx Biosciences has achieved two significant milestones for its therapeutic candidate, ozekibart. The submission of a Biologics License Application (BLA) to the FDA for conventional chondrosarcoma marks a critical step towards potential market approval, fulfilling a previously announced plan. Concurrently, updated interim data from the Phase 1/2 study in late-line colorectal cancer (CRC) demonstrated a compelling signal of activity, with an Objective Response Rate (ORR) of 20% compared to historical rates of 1-6% for standard of care in a heavily pretreated patient population. The median Progression-Free Survival (PFS) of 5.5 months and a robust Disease Control Rate (DCR) of 87% further underscore the drug's potential. These positive clinical results, coupled with a manageable safety profile, support the company's plans to discuss accelerated regulatory pathways and initiate a first-line registrational trial in CRC with the FDA. This dual progress significantly de-risks ozekibart's development and expands its potential market opportunity.